Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Angiotensin-converting enzyme inhibitor (ACEI)"'
Publikováno v:
The Egyptian Heart Journal, Vol 74, Iss 1, Pp 1-21 (2022)
Abstract Background Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are two of the most commonly used antihypertensive drugs acting on the renin–angiotensin–aldosterone system (RAAS). Previous research has
Externí odkaz:
https://doaj.org/article/a554ea179ed04ddfafd0b24af98c9852
Autor:
Jianqing She, Bowen Lou, Hui Liu, Bo Zhou, Gulinigaer Tuerhong Jiang, Yongbai Luo, Haoyu Wu, Chen Wang, Zuyi Yuan
Publikováno v:
ESC Heart Failure, Vol 8, Iss 6, Pp 4607-4616 (2021)
Abstract Aims This study aimed to compare the efficacy of angiotensin receptor‐neprilysin inhibitor (ARNI) therapy with angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy for cardiovascular outcomes in patien
Externí odkaz:
https://doaj.org/article/9a621fa9f0284f808822e5d7899f61f8
Publikováno v:
Contemporary Clinical Trials Communications, Vol 29, Iss , Pp 100968- (2022)
Objectives: To assess the efficacy and safety of losartan for COVID-19 patients. Methods: COVIDMED was a double-blinded, placebo-controlled platform RCT. Enrollees were randomized to standard care plus hydroxychloroquine, lopinavir/ritonavir, losarta
Externí odkaz:
https://doaj.org/article/c23d863ca79349a1b8c5697b2b6d7e19
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background While hypertension is the most common comorbid condition in patients with coronavirus disease 2019 (COVID-19) in Korea, there is a lack of studies investigating risk factors in COVID-19 patients with hypertension in Korea. In this
Externí odkaz:
https://doaj.org/article/0b3d259cab184292b99c4d13ae718609
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background To investigate the effects of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARBs) administration to hypertension patients with the coronavirus disease 2019 (COVID-19) induced pneumonia. Methods
Externí odkaz:
https://doaj.org/article/7cc659d9b7a14f2385b9835fdee54255
Autor:
Patrick Bidulka, Edouard L. Fu, Clémence Leyrat, Fotini Kalogirou, Katherine S. L. McAllister, Edward J. Kingdon, Kathryn E. Mansfield, Masao Iwagami, Liam Smeeth, Catherine M. Clase, Krishnan Bhaskaran, Merel van Diepen, Juan-Jesus Carrero, Dorothea Nitsch, Laurie A. Tomlinson
Publikováno v:
BMC Medicine, Vol 18, Iss 1, Pp 1-11 (2020)
Abstract Background The safety of restarting angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) after acute kidney injury (AKI) is unclear. There is concern that previous users do not restart ACEI/ARB despite on
Externí odkaz:
https://doaj.org/article/0fe9886e50034fe48ce305184b3d26d7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Medicine Science, Vol 5, Iss 3, Pp 751-7 (2016)
Hypertension and proteinuria are well-known predictors of chronic kidney disease (CKD) progression. Therapeutic interventions have different magnitude of albuminuria and hypertension. This study was designed to evaluate the efficacy and safety of com
Externí odkaz:
https://doaj.org/article/35f7bbde1caa4f32bd80454ead44f6fa
Autor:
Haoyu Wu, Yongbai Luo, Jianqing She, Bo Zhou, Gulinigaer Tuerhong Jiang, Bowen Lou, Chen Wang, Hui Liu, Zuyi Yuan
Publikováno v:
ESC Heart Failure, Vol 8, Iss 6, Pp 4607-4616 (2021)
ESC Heart Failure
ESC Heart Failure
Aims This study aimed to compare the efficacy of angiotensin receptor‐neprilysin inhibitor (ARNI) therapy with angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy for cardiovascular outcomes in patients with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f972859b787426d0cfd6f3d8d31f1c
https://doi.org/10.1002/ehf2.13644
https://doi.org/10.1002/ehf2.13644
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.